RecruitingNot ApplicableNCT05939674

Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam

Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam in Elderly Patients Undergoing Hip Joint Surgery: a Prospective Randomized Controlled Study.

Sponsor

Pusan National University Yangsan Hospital

Enrollment

24 participants

Start Date

Sep 19, 2023

Study Type

INTERVENTIONAL

Conditions

Elderly Patients Remimazolam Flumazenil Adverse Reaction Hip Joint

Summary

Remimazolam is a medication that has the advantage of a short half-life and reversibility with flumazenil. In clinical situations, the use of flumazenil for the reversal of sedation is common, but there is no precise indication for its administration. In this study, we aim to investigate the necessity of routine flumazenil use after administering remimazolam for intravenous anesthesia.

Eligibility

Min Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial investigates whether routinely giving the reversal drug flumazenil after anesthesia with remimazolam (a short-acting sedative) speeds up recovery for older patients undergoing hip surgery. Although flumazenil can reverse sedation quickly, it also has potential side effects, and there is currently no clear guidance on when it should be used. The study enrolls patients aged 65 and over scheduled for hip joint surgery who do not have neurological disorders, benzodiazepine dependence, or certain other medical conditions. Participation involves receiving either flumazenil or no reversal agent after surgery and being monitored for recovery speed and any complications. This summary was prepared to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFlumazenil

During induction, patients will receive remimazolam 6mg/kg/h with remifentanil TCI 1\~4 nanogram/mL. After patient loses consciousness, anesthesia will be maintained with remimazolam 1-2mg/kg/h combined with remifentanil. When procedure ends, infusion remimazolam stops and 0.3mg of flumazenil according to allocated groups.

DRUGnormal saline